Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Testosterone Undecanoate Followed by Enzalutamide in mCRPC
NCT05081193Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone undecanoate in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2022; status: active, not recruiting.
02
Drugs
testosterone undecanoate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05081193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081193.